Burning Rock Biotech (BNR) Cash & Equivalents: 2020-2025
Historic Cash & Equivalents for Burning Rock Biotech (BNR) over the last 6 years, with Sep 2025 value amounting to $65.2 million.
- Burning Rock Biotech's Cash & Equivalents fell 25.65% to $65.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.2 million, marking a year-over-year decrease of 25.65%. This contributed to the annual value of $71.2 million for FY2024, which is 17.79% down from last year.
- Latest data reveals that Burning Rock Biotech reported Revenue - Interest and Investment Income of $213.8 million as of Q2 2022.
- Over the past 5 years, Burning Rock Biotech's Cash & Equivalents peaked at $327.2 million during Q2 2021, and registered a low of $63.2 million during Q2 2025.
- Over the past 3 years, Burning Rock Biotech's median Cash & Equivalents value was $85.2 million (recorded in 2024), while the average stood at $85.3 million.
- Per our database at Business Quant, Burning Rock Biotech's Cash & Equivalents surged by 14,075.67% in 2021 and then plummeted by 48.45% in 2023.
- Burning Rock Biotech's Cash & Equivalents (MRQ) stood at $224.6 million in 2021, then tumbled by 41.55% to $131.3 million in 2022, then crashed by 34.01% to $86.6 million in 2023, then decreased by 17.79% to $71.2 million in 2024, then fell by 8.48% to $65.2 million in 2025.
- Its last three reported values are $65.2 million in Q3 2025, $63.2 million for Q2 2025, and $68.2 million during Q1 2025.